Bioavailability of everolimus administered as a single 5 mg tablet versus five 1 mg tablets: a randomized, open-label, two-way crossover study of healthy volunteers

BACKGROUND: The mammalian target of rapamycin (mTOR) inhibitor everolimus has a well-established pharmacokinetics profile. We conducted a randomized, single-center, open-label, two-sequence, two-period crossover study of healthy volunteers to assess the relative bioavailability of everolimus adminis...

Descripción completa

Detalles Bibliográficos
Autores principales: Thudium, Karen, Gallo, Jorge, Bouillaud, Emmanuel, Sachs, Carolin, Eddy, Simantini, Cheung, Wing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4310326/
https://www.ncbi.nlm.nih.gov/pubmed/25653564
http://dx.doi.org/10.2147/CPAA.S73472

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4310326/
https://www.ncbi.nlm.nih.gov/pubmed/25653564
http://dx.doi.org/10.2147/CPAA.S73472

Ejemplares similares